GITR抗体,Mouse Monoclonal GITR Antibody
  • GITR抗体,Mouse Monoclonal GITR Antibody
  • GITR抗体,Mouse Monoclonal GITR Antibody
  • GITR抗体,Mouse Monoclonal GITR Antibody

GITR抗体—艾普蒂

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 上海
更新日期 2025-05-15
QQ交谈 微信洽谈

产品详情

中文名称:GITR抗体英文名称:Mouse Monoclonal GITR Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 1124 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Mouse
偶联物: 靶点: GITR
2025-05-15 GITR抗体 Mouse Monoclonal GITR Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 1124 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC咨询技术 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM1/200 - 1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesTNFRSF18; AITR; CD357; GITR-D
Entrez GeneID8784
clone6H8B9
WB Predicted band size26kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human GITR (AA: 184-241) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    


  •  

     

       Flow cytometric analysis of HL-60 cells using GITR mouse mAb (green) and negative control (red).    


           

参考文献

以下是3篇关于GITR抗体的参考文献及其摘要概括:

---

1. **文献名称**:*Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-tumor Accumulation*

**作者**:Cohen AD, et al.

**摘要**:该研究探讨了激动型GITR抗体(DTA-1)在黑色素瘤小鼠模型中的作用,发现其通过抑制调节性T细胞(Tregs)的稳定性并减少肿瘤内Tregs的积累,从而增强效应T细胞的抗肿瘤活性,为GITR抗体联合免疫治疗提供了机制支持。

---

2. **文献名称**:*GITR Engagement Synergizes with PD-1 Blockade to Increase T Cell Priming and Antitumor Immunity*

**作者**:Lu L, et al.

**摘要**:研究表明,GITR抗体与PD-1抑制剂联用可显著增强T细胞活化和肿瘤特异性免疫应答。通过激活GITR信号通路,逆转T细胞耗竭,并在多种小鼠肿瘤模型中观察到协同抗肿瘤效果。

---

3. **文献名称**:*Glucocorticoid-Induced TNFR-Related Protein (GITR) Ligand as an Agonist of Costimulatory Signaling in CD8+ T Cells*

**作者**:Stephens GL, et al.

**摘要**:该文献揭示了GITR抗体通过结合CD8+ T细胞的GITR受体,直接增强其增殖与细胞因子分泌能力,同时抑制Treg的免疫抑制功能,为开发GITR靶向的癌症免疫疗法提供了理论基础。

---

**备注**:以上文献均发表于免疫学或肿瘤学期刊(如*Journal of Immunology*、*Cancer Research*等),可通过PubMed或Google Scholar搜索标题获取全文。如需更多文献或具体发表年份,可进一步补充检索。

       

背景信息

Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), also known as TNFRSF18. is a cell surface receptor belonging to the TNF receptor superfamily. Primarily expressed on regulatory T cells (Tregs) and activated effector T cells, GITR plays a dual role in immune regulation. Its interaction with its ligand (GITRL) enhances effector T cell activation, proliferation, and cytokine production, while simultaneously suppressing the immunosuppressive function of Tregs. This unique mechanism positions GITR as a promising therapeutic target for modulating antitumor immunity and autoimmune diseases.

GITR-targeting antibodies, typically designed as agonistic agents, aim to amplify antitumor responses by boosting effector T cell activity and overcoming Treg-mediated immune suppression. Preclinical studies in cancer models demonstrate that GITR agonism promotes tumor regression, often synergizing with checkpoint inhibitors like anti-PD-1/PD-L1 therapies. However, clinical trials have shown mixed results, with efficacy influenced by antibody design, dosing strategies, and patient selection. Some candidates, such as INCAGN01876 and MK-4166. have progressed to phase I/II trials, highlighting both safety profiles and variable tumor response rates. Challenges remain in optimizing target engagement and minimizing systemic immune-related adverse events. Current research focuses on combination therapies, biomarker identification, and engineering bispecific antibodies to enhance tumor-specific targeting.

       
关键字: GITR抗体;GITR;GITR Antibody;

公司简介

是一家科研、开发、生产和销售为一体的科技型企业,
成立日期 2024-07-02 (2年) 注册资本 20万人民币
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 抗体,蛋白组学,细胞生物学 经营模式 贸易,工厂,试剂,定制,服务
  • 上海切尔齐生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:20万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:重组蛋白、抗体、生物试剂
  • 公司地址:青浦区
询盘

GITR抗体—艾普蒂相关厂家报价

产品名称 价格   公司名称 报价日期
询价
VIP4年
武汉佰乐博生物技术有限公司
2026-02-05
¥2600.00
VIP10年
北京索莱宝科技有限公司
2026-02-04
询价
VIP3年
北京百普赛斯生物科技股份有限公司
2026-01-22
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.